Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TrRaMM-TMI: Treosulfan/TMI Conditioning for Allo-HSCT
NCT03963024Phase 1Terminated
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Feb 2014
- Primary completion
- Jan 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of treosulfan and sirolimus in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM), sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: Maximum Tolerated Dose of Total Marrow Irradiation and Rate of Survival post transplant. Started Feb 2014; status: terminated.
02
Drugs
treosulfansirolimus
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03963024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03963024.